Krzeski, Piotr <br/><br/>
Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study.  [electronic resource] 

 -  Arthritis research & therapy  2007 
 - R109 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1478-6362 
<br/><br/><label>Standard No.: </label>10.1186/ar2315  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Double-Blind Method<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Hydroxamic Acids--administration & dosage<br/>Male<br/>Matrix Metalloproteinase Inhibitors<br/>Matrix Metalloproteinases--metabolism<br/>Middle Aged<br/>Musculoskeletal Diseases--chemically induced<br/>Osteoarthritis, Knee--drug therapy<br/>Protease Inhibitors--administration & dosage